名創優品(09896.HK)遭殺人鯨資本沽空 美股跌近15%
沽空機構殺人鯨資本(Blue Orca Capital)發表報告沽空名創優品(09896.HK)(MNSO.US),表示經過7個月調查後,發現根據中國企業記錄和門店數據顯示,名創優品旗下數百家門店是由高層或董事長關係密切的人士所擁有和經營,而並非公司所聲稱的由加盟商經營。
報告又指,名創優品虛報核心商業模式,收入前景不明,同時董事長涉嫌透過與公司開設一家英屬維爾京群島合資企業,利用總部建設工作從上市公司轉走資金。
名創優品美股隔晚跌近15%,收報6.13美元。
集團則回應指有關沽空報告毫無依據,當中包含有關公司資料為誤導性結論及詮釋,考慮對此採取適當行動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.